INBX - Inhibrx, Inc. Stock Price, Fair Value and News

34.38USD+0.25 (+0.73%)Market Closed

Market Summary

USD34.38+0.25

Market Closed

0.73%

INBX Stock Price

View Fullscreen

INBX RSI Chart

INBX Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-6.7

Price/Sales (Trailing)

135.73

EV/EBITDA

-6.32

Price/Free Cashflow

-8.17

INBX Price/Sales (Trailing)

INBX Profitability

EBT Margin

-2011.61%

Return on Equity

-554.81%

Return on Assets

-78.39%

Free Cashflow Yield

-12.24%

INBX Fundamentals

INBX Revenue

Revenue (TTM)

11.9M

Rev. Growth (Yr)

300%

Rev. Growth (Qtr)

87.86%

INBX Earnings

Earnings (TTM)

-241.4M

Earnings Growth (Yr)

-128.78%

Earnings Growth (Qtr)

-80.74%

Breaking Down INBX Revenue

Last 7 days

-1.4%

Last 30 days

-2.2%

Last 90 days

-5.9%

Trailing 12 Months

64.1%

How does INBX drawdown profile look like?

INBX Financial Health

Current Ratio

5.25

INBX Investor Care

Shares Dilution (1Y)

8.77%

Diluted EPS (TTM)

-5.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	4.5M	7.0M	9.5M	11.9M
2022	7.3M	5.5M	3.8M	2.1M
2021	12.9M	10.5M	7.2M	7.2M
2020	13.1M	13.0M	13.0M	12.9M
2019	0	0	0	13.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Inhibrx, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 28, 2023	viking global investors lp	bought	9,899,980	19.35	511,627	-
Mar 01, 2023	eckelman brendan p.	sold	-968,231	24.2058	-40,000	chief scientific officer
Feb 28, 2023	lappe mark	sold	-1,501	25.0208	-60.00	chief executive officer
Feb 02, 2023	eckelman brendan p.	sold	-286,355	25.4537	-11,250	chief scientific officer
Feb 01, 2023	eckelman brendan p.	sold	-710,856	24.7254	-28,750	chief scientific officer
Jan 24, 2023	lappe mark	sold	-111,478	25.7159	-4,335	chief executive officer
Jan 23, 2023	lappe mark	sold	-549,364	25.3572	-21,665	chief executive officer
Jan 23, 2023	kayyem jon faiz	sold	-239,999	25.2631	-9,500	-
Jan 04, 2023	eckelman brendan p.	sold	-166,829	23.4805	-7,105	chief scientific officer
Jan 03, 2023	eckelman brendan p.	sold	-781,770	23.7656	-32,895	chief scientific officer

Which funds bought or sold INBX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-72.33	-121,000	41,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	357,512	691,372	-%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	added	2.5	-64,633	1,068,410	0.06%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	21.45	29,889	284,679	0.01%
Apr 15, 2024	Concurrent Investment Advisors, LLC	new	-	412,072	412,072	0.02%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Apr 05, 2024	GAMMA Investing LLC	added	210	699	1,084	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	1,178	1,178	-%
Mar 11, 2024	VANGUARD GROUP INC	added	4.72	38,381,200	71,224,300	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	92.11	8,715,420	11,641,700	-%

Are Funds Buying or Selling INBX?

Are funds buying INBX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INBX

No. of Funds

Unveiling Inhibrx, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	eckelman brendan p.	4.3%	2,035,553	SC 13G/A
Feb 14, 2024	kayyem jon faiz	7.0%	3,308,123	SC 13G/A
Feb 14, 2024	lappe mark	5.2%	2,486,192	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	9.99%	4,724,352	SC 13G/A
Feb 14, 2024	perceptive advisors llc	9.9%	4,776,306	SC 13G/A
Feb 14, 2024	viking global investors lp	15.1%	7,150,826	SC 13G/A
Jan 29, 2024	blackrock inc.	5.7%	2,715,672	SC 13G/A
Jan 23, 2024	state street corp	3.46%	1,635,726	SC 13G/A
Mar 09, 2023	inhibrx, inc.	5.8%	2,512,252	SC 13G/A
Mar 09, 2023	inhibrx, inc.	4.9%	2,155,553	SC 13G/A

Recent SEC filings of Inhibrx, Inc.

View All Filings

Date Filed	Form Type	Document
Mar 28, 2024	4	Insider Trading
Mar 26, 2024	144	Notice of Insider Sale Intent
Mar 22, 2024	144	Notice of Insider Sale Intent
Mar 22, 2024	4	Insider Trading
Mar 21, 2024	144	Notice of Insider Sale Intent
Mar 20, 2024	144	Notice of Insider Sale Intent
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 13, 2024	144	Notice of Insider Sale Intent
Mar 13, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Inhibrx, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Inhibrx, Inc. News

Latest updates

Inhibrx, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Revenue	-	-	-	2,414,000	1,285,000	156,000	278,000	603,500	929,000	2,856,000	2,532,000	954,000	889,000	2,776,000	5,901,000	3,339,000	872,000	1,045,500	1,219,000
Operating Expenses	95.7%	89,923,000	45,946,000	41,369,000	43,783,000	35,774,000	30,281,000	35,308,000	29,946,000	22,260,000	21,333,000	20,755,000	19,447,000	19,883,000	21,459,000	20,506,000	18,483,000	-	14,266,000
S&GA Expenses	-0.7%	7,832,000	7,889,000	7,263,000	6,397,000	5,323,000	5,347,000	5,402,000	5,051,000	3,645,000	2,848,000	2,853,000	3,009,000	2,215,000	1,622,000	1,532,000	1,467,000	-	1,481,000
R&D Expenses	115.7%	82,091,000	38,057,000	34,106,000	37,386,000	30,451,000	24,934,000	29,906,000	24,895,000	18,615,000	18,485,000	17,902,000	16,438,000	17,668,000	19,837,000	18,974,000	17,016,000	-	12,785,000
EBITDA Margin	-Infinity%	-17.77	-	-74.62	-68.68	-59.72	-29.48	-18.46	-12.07	-10.60	-10.45	-7.10	-5.64	-5.75	-	-	-	-	-
Interest Expenses	-	-	-	6,672,000	6,276,000	5,256,000	3,859,000	2,473,000	1,502,000	1,888,000	679,000	725,000	597,000	332,000	133,000	-	39,000	-	-
Income Taxes	-300.0%	-4,000	2,000	5,000	-	-1,000	-	4,000	-	-	-	-	2,000	3,000	-	-	-	-	900,000
Earnings Before Taxes	-77.6%	-91,974,000	-51,787,000	-47,047,000	-48,916,000	-40,916,000	-35,325,000	-37,728,000	-31,254,000	-21,189,000	-20,580,000	-20,710,000	-19,287,000	-17,646,000	-20,010,000	-17,885,000	-20,093,000	-	-19,263,000
EBT Margin	-0.8%	-20.12	-19.95	-86.27	-77.79	-66.25	-32.30	-19.85	-12.89	-11.31	-10.94	-7.38	-5.80	-	-	-	-	-	-
Net Income	-80.7%	-93,604,000	-51,789,000	-47,052,000	-48,916,000	-40,915,000	-35,325,000	-37,732,000	-31,254,000	-21,189,000	-20,580,000	-20,710,000	-19,289,000	-17,649,000	-20,497,000	-17,885,000	-20,093,000	-16,305,000	-20,163,000
Net Income Margin	-1.5%	-20.25	-19.95	-86.28	-77.79	-66.25	-32.30	-19.86	-12.89	-11.31	-10.94	-7.43	-5.84	-	-	-	-	-	-
Free Cashflow	-9.5%	-60,263,000	-55,056,000	-42,616,000	-39,967,000	-30,867,000	-30,818,000	-27,244,000	-27,058,000	-22,887,000	-13,844,000	-22,794,000	-21,662,000	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-17.4%	308	373	213	254	291	165	193	161	150	129	142	125	144	144	26.00
Current Assets	-18.7%	295	363	203	244	280	154	182	150	139	119	131	113	132	132	16.00
Cash Equivalents	-17.6%	278	337	192	234	274	146	176	143	131	113	126	108	129	128	12.00
Net PPE	124.1%	6.00	3.00	3.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
Liabilities	8.7%	264	243	238	239	233	200	198	134	98.00	101	98.00	64.00	68.00	52.00	61.00
Current Liabilities	57.4%	56.00	36.00	31.00	33.00	28.00	25.00	24.00	20.00	22.00	25.00	22.00	28.00	31.00	35.00	21.00
Shareholder's Equity	-66.4%	44.00	130	-	15.00	58.00	-	-	27.00	52.00	28.00	44.00	61.00	75.00	92.00	-
Retained Earnings	-18.0%	-613	-520	-468	-421	-372	-331	-296	-258	-227	-206	-185	-164	-145	-127	-69.25
Additional Paid-In Capital	1.2%	657	650	444	436	430	296	291	286	280	234	230	225	221	219	-24.32
Shares Outstanding	0.2%	47.00	47.00	44.00	44.00	44.00	39.00	39.00	39.00	39.00	38.00	38.00	38.00	-	-	-
Float	-	-	-	893	-	-	-	331	-	-	-	764	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-4.7%	-56,821	-54,245	-42,299	-39,944	-30,600	-30,838	-26,922	-26,941	-22,620	-13,675	-22,380	-21,648	-15,389	-13,882	-11,309	-7,388	-	-
Share Based Compensation	-1.6%	6,427	6,530	6,253	5,636	5,355	4,691	5,296	5,108	4,183	3,493	3,951	3,421	1,373	1,303	1,259	1,088	-	-
Cashflow From Investing	-324.4%	-3,442	-811	-317	-23.00	-267	20.00	-322	-117	-267	-169	-359	-14.00	-612	-299	-362	-91.00	-	-
Cashflow From Financing	-99.6%	860	199,891	854	356	158,659	506	60,162	39,224	41,484	820	40,477	988	16,996	136,218	16,875	-3,633	-	-

INBX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 1,800	$ 2,192
Operating expenses:
Research and development	191,640	110,186
General and administrative	29,381	21,123
Total operating expenses	221,021	131,309
Loss from operations	(219,221)	(129,117)
Other income (expense):
Interest expense	(31,840)	(18,181)
Interest income	11,917	2,074
Other income (expense), net	(580)	1
Total other expense	(20,503)	(16,106)
Loss before provision for income taxes	(239,724)	(145,223)
Provision for income taxes	3	3
Loss from equity method investment	1,634	0
Net loss	$ (241,361)	$ (145,226)
Net loss per share, basic (in dollars per share)	$ (5.12)	$ (3.62)
Net loss per share, diluted (in dollars per share)	$ (5.12)	$ (3.62)
Weighted-average shares of common stock outstanding, basic (in shares)	47,130	40,108
Weighted-average shares of common stock outstanding, diluted (in shares)	47,130	40,108
License fee revenue
Revenue:
Total revenue	$ 1,800	$ 2,178
Grant revenue
Revenue:
Total revenue	$ 0	$ 14

INBX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 277,924	$ 273,865
Prepaid expenses and other current assets	16,656	6,371
Total current assets	295,358	280,493
Property and equipment, net	6,419	2,501
Operating right-of-use asset	2,952	4,717
Other non-current assets	3,164	3,164
Total assets	307,893	290,875
Current liabilities:
Accounts payable	10,954	8,326
Accrued expenses	43,295	17,224
Deferred revenue	0	166
Current portion of lease liability	2,063	1,860
Total current liabilities	56,312	27,576
Long-term debt, including final payment fee	206,968	202,069
Non-current portion of lease liability	1,110	3,173
Total liabilities	264,390	232,818
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 15,000,000 shares authorized and no shares outstanding as of December 31, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value, 120,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 47,369,511 and 43,564,283 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	5	4
Additional paid-in-capital	657,232	430,426
Accumulated deficit	(613,734)	(372,373)
Total stockholders’ equity	43,503	58,057
Total liabilities and stockholders’ equity	307,893	290,875
Nonrelated Party
Current assets:
Accounts receivable	778	243
Related Party
Current assets:
Accounts receivable	$ 0	$ 14

About Inhibrx, Inc.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.

CEO	Mr. Mark Paul Lappe
WEBSITE	https://inhibrx.com
INDUSTRY	Biotechnology
EMPLOYEES	132

Inhibrx, Inc. Frequently Asked Questions

What is the ticker symbol for Inhibrx, Inc.? What does INBX stand for in stocks?

INBX is the stock ticker symbol of Inhibrx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inhibrx, Inc. (INBX)?

As of Tue Apr 23 2024, market cap of Inhibrx, Inc. is 1.62 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INBX stock?

You can check INBX's fair value in chart for subscribers.

What is the fair value of INBX stock?

You can check INBX's fair value in chart for subscribers. The fair value of Inhibrx, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Inhibrx, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INBX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Inhibrx, Inc. a good stock to buy?

The fair value guage provides a quick view whether INBX is over valued or under valued. Whether Inhibrx, Inc. is cheap or expensive depends on the assumptions which impact Inhibrx, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INBX.

What is Inhibrx, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, INBX's PE ratio (Price to Earnings) is -6.7 and Price to Sales (PS) ratio is 135.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INBX PE ratio will change depending on the future growth rate expectations of investors.